[{"address1": "2265 Upper Middle Road East", "address2": "Suite 602", "city": "Oakville", "state": "ON", "zip": "L6H 0G5", "country": "Canada", "phone": "289-910-0850", "fax": "905-481-2394", "website": "https://www.cardiolrx.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. David G. Elsley MBA", "title": "President, CEO & Director", "fiscalYear": 2023, "totalPay": 548110, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA", "title": "CFO, Corporate Secretary & Director", "fiscalYear": 2023, "totalPay": 215991, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bernard  Lim B.Sc.", "title": "Chief Operating Officer", "fiscalYear": 2023, "totalPay": 377984, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew Warwick Hamer M.D.", "age": 61, "title": "Chief Medical Officer & Head of Research & Development", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 546984, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Trevor  Burns", "title": "Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.12, "dayLow": 2.09, "dayHigh": 2.2, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.12, "regularMarketDayLow": 2.09, "regularMarketDayHigh": 2.2, "beta": 0.672, "forwardPE": -7.316666, "volume": 175803, "regularMarketVolume": 175803, "averageVolume": 508818, "averageVolume10days": 238750, "averageDailyVolume10Day": 238750, "bid": 2.17, "ask": 2.2, "bidSize": 400, "askSize": 100, "marketCap": 151451280, "fiftyTwoWeekLow": 0.661, "fiftyTwoWeekHigh": 3.12, "fiftyDayAverage": 2.2229, "twoHundredDayAverage": 1.46052, "currency": "USD", "enterpriseValue": 118560568, "floatShares": 65707783, "sharesOutstanding": 68998304, "sharesShort": 888481, "sharesShortPriorMonth": 374019, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0128999995, "heldPercentInsiders": 0.046269998, "heldPercentInstitutions": 0.13236, "shortRatio": 1.08, "shortPercentOfFloat": 0.0135, "impliedSharesOutstanding": 69106000, "bookValue": 0.294, "priceToBook": 7.4659863, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -30218588, "trailingEps": -0.34, "forwardEps": -0.3, "enterpriseToEbitda": -3.923, "52WeekChange": 1.762646, "SandP52WeekChange": 0.2362777, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CRDL", "underlyingSymbol": "CRDL", "shortName": "Cardiol Therapeutics Inc.", "longName": "Cardiol Therapeutics Inc.", "firstTradeDateEpochUtc": 1547562600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ee9d962b-eed4-3063-8df9-c815990fe5d8", "messageBoardId": "finmb_424954803", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.195, "targetHighPrice": 9.98, "targetLowPrice": 7.98, "targetMeanPrice": 8.98, "targetMedianPrice": 8.98, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 28572976, "totalCashPerShare": 0.414, "ebitda": -30222164, "totalDebt": 167136, "quickRatio": 2.646, "currentRatio": 2.807, "debtToEquity": 0.833, "returnOnAssets": -0.45347, "returnOnEquity": -0.92109, "freeCashflow": -9735083, "operatingCashflow": -22156452, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-07-16"}]